Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301).

医学 膀胱癌 佐剂 丝裂霉素C 尿路上皮癌 泌尿科 随机对照试验 癌症 肿瘤科 辅助治疗 内科学 外科
作者
Dickon Hayne,Alison Yan Zhang,Hayley Thomas,Stephen P. McCombie,Cynthia Hawks,Paul Anderson,Patricia A. Bastick,Emma Kate Beardsley,William Green,Mark Frydenberg,Jeremy Grummet,Joseph J. Ischia,Laurence Eliot Miles Krieger,Andrew J. Mitterdorfer,Manish I. Patel,Shomik Sengupta,Ratnesh Kumar Srivastav,Andrew David Redfern,Ian D. Davis,Martin R. Stockler
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (17_suppl) 被引量:7
标识
DOI:10.1200/jco.2025.43.17_suppl.lba4504
摘要

LBA4504 Background: Intravesical BCG is the standard of care for high-risk non-muscle invasive bladder (NMIBC) after maximal transurethral resection. Availability and access to BCG have been a global challenge since 2013. We sought to determine the efficacy and safety of intravesical treatment with BCG plus mitomycin (BCG+MM) compared with BCG-alone for high-risk, BCG-naïve NMIBC. Methods: This was an open-label, randomized, phase 3 trial. Eligible participants (pts) had high-grade papillary urothelial cancer stages pTa/pT1; concurrent CIS was allowed. Pts were randomly assigned BCG+MM vs BCG-alone. The BCG+MM regimen was weekly induction x 9 (BCG wks 1, 2, 4, 5, 7, and 8; MM wks 3, 6, and 9) followed by 4-weekly maintenance x 9 (MM wks 13, 17, 25, 29, 37, and 41; BCG wks 21, 33, and 45: total of 9 BCG doses). The BCG-alone regimen was weekly induction x 6, then 4-weekly maintenance x 10: total of 16 BCG doses. The primary endpoint was disease-free survival (DFS) at 2 years; secondary outcomes included complete response on cystoscopy at 3 months (CR3mos), time-to-recurrence (TTR), time-to-progression (TTP), overall survival (OS) and adverse events (AE). The target sample size of 500 provided 85% power to detect an absolute improvement of 10% in DFS at 2 years with a type-1 error rate of 0.05. Cox regression was used to calculate hazard ratios (HR), confidence intervals (CI), and account for competing risks. P-values are 2-sided and not adjusted for multiple comparisons. Clinicaltrials.gov NCT02948543. Results: We enrolled 501 pts from DEC2013 to MAY2023: median age 70 years (IQR 63-77); pTa 53%, pT1 47%, concurrent CIS 28%. In this primary analysis, the median follow-up was 47 months (IQR 31-64) at the data cut-off of 06DEC2024. Analyses of all key endpoints (DFS, CR3mos, TTR, TTP and OS) supported similar efficacy in the 2 treatment groups (see table), but none with p<0.05. The total numbers of instillations were higher for BCG+MM than BCG-alone (4,034 vs 3,383), whereas the total doses of BCG (2,056 vs 3,383), and median doses of BCG per pt (9 vs 16) were lower for BCG+MM than BCG-alone. The numbers of pts with grade 3-5 AEs were 43 in BCG-MM vs 37 in BCG-alone. The AE (of any grade) reported by the highest numbers of pts (BCG+MM vs BCG-alone) were fatigue (109 vs 110), renal/urinary (78 vs 83), and flu-like symptoms (34 vs 60). More pts had ≥75% of their planned doses with BCG+MM than BCG-alone (78% vs 68%; p=0.02). Conclusions: BCG+MM had similar efficacy and safety, but with fewer treatment discontinuations and fewer doses of BCG than BCG-alone. BCG+MM is a good alternative to BCG-alone. Clinical trial information: NCT02948543 . BCG+MM N=248 BCG-aloneN=252 HR (95% CI) p-value DFS at 2 years 76% 71% 0.86 (0.64-1.14) 0.30 CR at 3 months 90% 86% 1.05 (0.98-1.12) 0.22 Recurrence-free at 2 years 81% 75% 0.84 (0.61-1.18) 0.31 Progression-free at 5 years 87% 81% 0.74 (0.45-1.21) 0.23 OS at 5 years 87% 87% 1.07 (0.61-1.88) 0.81

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被Chenzr采纳,获得10
1秒前
1秒前
ding的应助被柴六斤采纳,获得10
2秒前
科研大佬修炼手册给科研大佬修炼手册的求助进行了留言
2秒前
科研狂人发布了新的文献求助10
2秒前
2秒前
sqqx发布了新的文献求助10
2秒前
大模型的应助被2499297293采纳,获得10
3秒前
3秒前
在望的应助被LW采纳,获得10
3秒前
3秒前
drizzle发布了新的文献求助10
3秒前
小6完成签到 ,获得积分10
3秒前
3秒前
jie完成签到,获得积分10
4秒前
4秒前
4秒前
情怀的应助被xu采纳,获得10
5秒前
5秒前
5秒前
大力山槐完成签到,获得积分10
5秒前
5秒前
6秒前
sunny完成签到 ,获得积分10
6秒前
复杂秀发发布了新的文献求助10
7秒前
思源的应助被冷酷的酒窝采纳,获得10
7秒前
陈1完成签到 ,获得积分10
7秒前
QINJINGRUI完成签到,获得积分10
7秒前
XiYang完成签到,获得积分20
8秒前
文昌完成签到 ,获得积分10
8秒前
ttttt发布了新的文献求助10
9秒前
9秒前
阿馅儿完成签到,获得积分10
9秒前
9秒前
9秒前
_响_发布了新的文献求助10
9秒前
hu完成签到 ,获得积分10
10秒前
余香的应助被123采纳,获得10
10秒前
亲亲完成签到 ,获得积分10
10秒前
阔达翠彤发布了新的文献求助200
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175556
求助须知:如何正确求助?哪些是违规求助? 9567240
关于积分的说明 21791502
捐赠科研通 7770174
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299